Crinetics Pharmaceuticals (CRNX) Stock Looks Overvalued Despite Strong 3 Year Returns

Crinetics Pharmaceuticals has delivered a very strong share price run over the past three years, yet its current valuation screens as expensive on market multiples and the broader checks only give it a mixed score. That combination leaves investors weighing a powerful recent return against signals that the stock is not clearly cheap at today’s price of US$84.75.

• Crinetics Pharmaceuticals has returned 428.0% over the past three years, which sets a high bar for any further gains to be supported by fundamentals.
• Expectations for future revenue growth can support a premium valuation, but ongoing development costs and the time required to turn pipeline assets into cash flow may limit how much investors are willing to pay up.
• The stock screens as overvalued on traditional market multiples and, with a value score of 3 out of 6, the overall picture is a mixed one rather than a clear bargain or clear overvaluation.

The issue now is whether Crinetics Pharmaceuticals' current price fairly reflects its prospects after such a strong run, or whether expectations have moved ahead of the underlying business.

Crinetics Pharmaceuticals delivered 185.0% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Has Crinetics Pharmaceuticals Run Too Far on Book Value?

P/B is often a useful check for a company such as Crinetics Pharmaceuticals because investors are effectively paying for a mix of cash on the balance sheet and research assets that are not yet producing consistent cash flow.

On this measure, Crinetics Pharmaceuticals trades at a P/B of 7.5x, compared with an industry average of about 2.5x for pharmaceuticals. That is a large premium to the typical company in the sector and indicates that the market is placing a high value on the future potential of its pipeline relative to its current net assets.

The peer group screens nearer 48.9x on P/B, which is much higher, but the model flags that gap as extreme. The framework is heavily penalising losses and risk for some peers, so the peer number looks more like a warning about how expensive many stocks appear on this metric rather than a precise comparison point. For Crinetics Pharmaceuticals, the main takeaway is that the stock still carries a rich valuation versus the industry on a simple P/B check.

On balance, Crinetics Pharmaceuticals appears expensive on its current P/B multiple compared with the broader pharmaceuticals sector.

See what the numbers say about this price — find out in our valuation breakdown.

The Crinetics Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Crinetics Pharmaceuticals pick up where the P/B discussion leaves off and explain which combinations of growth, margins and earnings would need to unfold for the stock to be worth materially more or less than today’s price. Where a single ratio or model outputs one number, Narratives unpack the future business path that number depends on so you can watch how Crinetics Pharmaceuticals' real progress lines up over time. They are available on Simply Wall St's Community page.

One of the top community narratives on Crinetics Pharmaceuticals: roughly fairly valued

"Recent research on Crinetics Pharmaceuticals points to a clear shift in focus toward the US$85 per share cash offer from Vertex Pharmaceuticals as the key reference point for valuation…"

Read one of the top narratives on Crinetics Pharmaceuticals

Do you think there's more to the story for Crinetics Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

Crinetics Pharmaceuticals now looks overvalued on the key market multiples used in the checks above, with expectations stretched after a very strong multi year move. The mixed overall valuation profile means the stock is not an obvious bargain, but the market is clearly assigning considerable value to its future pipeline potential. The real split between bulls and bears is how much confidence you place in that potential turning into commercially meaningful products on a timeline that still justifies paying this kind of premium today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com